echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The 15 provinces have not been evaluated drug procurement alliance is coming! Price accounts for only 40% of the factor

    The 15 provinces have not been evaluated drug procurement alliance is coming! Price accounts for only 40% of the factor

    • Last Update: 2022-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On October 28, Jiangxi released a draft for comments on the collective procurement of unevaluated varieties led by the province in 15 provinces, and written feedback can be provided
    before November 2.
     
    The provinces involved are: Jiangxi, Inner Mongolia, Jilin, Heilongjiang, Zhejiang, Henan, Hunan, Guangxi, Hainan, Guizhou, Shaanxi, Qinghai, Ningxia, Xinjiang and the Xinjiang Production and Construction Corps
    .
     
    Fifteen varieties are shown in the table below, including papaverine, topsyejun, gangliosides, etc
     
     
    The 15 provincial alliance plans to conduct comprehensive reviews
    using a two-envelope model.
    Economic and technical standards and business standards open 6:4
     
    It is worth noting that Jiangxi led the 15 provincial alliances to conduct comprehensive evaluation in the two-envelope mode, and the weight of economic and technical standards and commercial standards was 6:4.
     
    The products of the 1 company with the lowest quotation and the 1 company with the highest comprehensive evaluation score are to be selected; If the company with the lowest quotation and the highest overall score are the same company, only 1 company
    will be selected.
     
    It can be seen that Jiangxi Alliance pays attention to the balance of technology and price, but pays more attention to the scoring role
    of technical targets.
     
    The economic and technical bids are evaluated based on the drug name and the combined dosage form of medical insurance, and the highest economic and technical standard score of the products of each reporting enterprise is evaluated
    .
    Score ranked
    from highest to lowest.
     
    The economic and technical standard score is roughly composed of the following aspects:
     
    Quality index (69 points): mainly product quality level, divided into 6 aspects, such as original research, past evaluation, Europe, America and Japan listing, etc.
    , the score is not cumulative, and the highest score shall prevail;
     
    Supply security index (13 points): different points are assigned according to the distribution rate index;
     
    Comprehensive indicators (18 points): including several indicators such as untrustworthy recruitment records, national procurement selection, market share, coverage of medical institutions, and industry rankings, with different
    scores.
     
    It can be seen that for the collective procurement of unevaluated varieties, the quality level is still very important, especially the original research, reference preparations and evaluated varieties almost belong to the "first quality level" in the traditional sense, which is very different
    from the national collective procurement for the original research and the evaluated varieties, without distinguishing between the quality level.
     
    The agreed purchase quantity of each variety in the first year shall be determined according to the following rules:
     
    If one enterprise is selected, 50% of the agreed procurement volume base in the first year shall be the agreed procurement volume in the first year;
     
    2 For the selected one, 75% of the agreed procurement volume base in the first year is the agreed procurement volume in the first year, of which 50% is used as the agreed procurement volume of the enterprise selected at the lowest price, and 25% is used as the agreed purchase volume
    of the enterprise with the highest score in the first year.
     
    How to deal with the overlapping results of the 15 provincial alliance collective procurement and the national procurement
     
    During the procurement cycle, when the results of the centralized drug procurement organized by the state overlap with the results of the centralized drug procurement, if the selected enterprises are different, the results of the selection of the alliance region can be implemented in the first year, and the results of the national selection can be implemented when the contract is renewed in the second year; If the selected enterprises are the same but the prices are different, the results of the selection with the lower price will be executed
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.